cilastatin has been researched along with Airflow Obstruction, Chronic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cizmeci, Z; Dereli, N; Günay, E; Küçükbayrak, A; Uğurman, F | 1 |
| Amato, G; Bariffi, F; Giacomelli, P; Nani, E; Sanduzzi, A | 1 |
| Ding, X; Hu, S; Nie, H; Peng, Y; Wu, X | 1 |
3 other study(ies) available for cilastatin and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
[A community acquired pneumonia case caused by Ralstonia pickettii].
Topics: Anti-Bacterial Agents; Cilastatin; Cilastatin, Imipenem Drug Combination; Community-Acquired Infections; Drug Combinations; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Middle Aged; Opportunistic Infections; Pneumonia, Bacterial; Protease Inhibitors; Pulmonary Disease, Chronic Obstructive; Ralstonia pickettii; Treatment Outcome | 2009 |
Imipenem/cilastatin as monotherapy in the treatment of acute or chronic lung infections: clinical efficacy and safety.
Topics: Acute Disease; Adult; Aged; Bacterial Infections; Chronic Disease; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Female; Humans; Imipenem; Lung Diseases; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia; Pulmonary Disease, Chronic Obstructive; Safety | 1989 |
Risk factors of superinfection following imipenem/cilastatin therapy in hospitalised patients with acute exacerbations of severe chronic obstructive pulmonary disease.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Cilastatin; Critical Care; Drug Combinations; Female; Hospitalization; Humans; Imipenem; Male; Middle Aged; Prospective Studies; Protease Inhibitors; Pulmonary Disease, Chronic Obstructive; Regression Analysis; Risk Factors; Superinfection | 2006 |